None (ALNY) SEC News Oct. 30, 2025, 00:00 UTC (4% Negative) ALNYLAM PHARMACEUTICALS, INC. (ALNY) Reports 253% Loss Increase for 2025-09-30 Full text
Register to leave comments News bot Nov. 2, 2025, 10:20 a.m. 🏢 None (ALNY) - Form 10-Q Quarterly Report Quarterly financial filing submitted to the SEC 📋 Filing Information 📄 Form Type: 10-Q 📅 Filing Date: 2025-10-30 📊 Period of Report: 2025-09-30 ⏰ Accepted: N/A 📊 Key Financial Metrics (Period-over-Period Comparison) Metric Current Period Previous Period Change ($) Change (%) Trend Net Income/Loss $-194.39M $127.33M $-321.72M -252.67% 📈 Total Assets $4.24B $4.85B $-611.68M -12.61% 📉 Total Liabilities $4.17B $4.62B $-444.87M -9.63% 📈 Stockholders' Equity $-24.83M $4.29M $-29.12M -678.02% 📉 Operating Income/Loss $-71.73M $369.86M $-441.59M -119.39% 📈 R&D Expense $826.06M $947.56M $-121.49M -12.82% 📈 SG&A Expense $680.19M $885.34M $-205.15M -23.17% 📈 Earningspersharebasic $-1.53 $0.98 $-2.51 -256.12% 📉 Earningspersharediluted $-1.53 $0.95 $-2.48 -261.05% 📉 📈 Financial Trend Analysis 🔻 Reported net loss for the period 📎 View Full 10-Q Filing on SEC.gov Access the complete official filing document
🏢 None (ALNY) - Form 10-Q Quarterly Report
📋 Filing Information
Key Financial Metrics (Period-over-Period Comparison)
Financial Trend Analysis
🔻 Reported net loss for the period
📎 View Full 10-Q Filing on SEC.gov
Access the complete official filing document